DPP-4i Treatment Doesn't Up MI, Stroke Risk in Seniors

This article originally appeared here.
Share this content:
DPP-4i Treatment Doesn't Up MI, Stroke Risk in Seniors
DPP-4i Treatment Doesn't Up MI, Stroke Risk in Seniors

FRIDAY, Feb. 24, 2017 (HealthDay News) -- For older U.S. Medicare beneficiaries, dipeptidyl peptidase-4 inhibitors (DPP-4i) treatment is not associated with increased cardiovascular (CV) risk relative to sulfonylureas (SU) and thiazolidinediones (TZD), according to a study published online Feb. 14 in Diabetes, Obesity and Metabolism.

Mugdha Gokhale, Ph.D., from the University of North Carolina at Chapel Hill, and colleagues identified two new-user cohorts of Medicare beneficiaries aged >65 years: DPP-4i versus SU (30,130 and 68,382 initiators, respectively) and DPP-4i versus TZD (20,596 and 13,526, respectively) during 2007 to 2013.

The researchers found that the hazard ratio for the composite outcome (myocardial infarction [MI], stroke, and all-cause mortality) was 0.75 (95 percent confidence interval [CI], 0.72 to 0.79) in the DPP-4i versus SU comparison. For DPP-4i and SU, respectively, the one-year risks for MI were 1.00 (95 percent CI, 0.89 to 1.12) and 1.47 (95 percent CI, 1.38 to 1.56) per 100 patients; the corresponding numbers for stroke risk were 0.98 (95 percent CI, 0.87 to 1.10) and 1.09 (95 percent CI, 1.01 to 1.17). For DPP-4i versus TZD, the hazard ratio for the composite outcome was 0.94 (95 percent CI, 0.86 to 1.02). The one-year risks for MI and stroke were about 0.90 and 0.80, respectively, per 100 patients for both DPP-4i and TZD.

"Though limited by the short treatment duration, our study suggests no increased short-term risk of MI stroke or heart failure with DPP-4i versus SU/TZD," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Aspirin, Rivaroxaban Similar After Total Hip, Knee Arthroplasty

Aspirin, Rivaroxaban Similar After Total Hip, Knee Arthroplasty

Extended prophylaxis with aspirin no different from rivaroxaban for preventing venous thromboembolism

Odds of ARDS Up After Cardiac Surgery During Flu Season

Odds of ARDS Up After Cardiac Surgery During ...

Cardiac surgery during flu season is independent risk factor for acute respiratory distress syndrome

In A-Fib Patients, Stroke Risk Higher for Blacks Than Whites

In A-Fib Patients, Stroke Risk Higher for Blacks ...

Higher risk of ischemic stroke seen before, after atrial fibrillation diagnosis compared with whites

is free, fast, and customized just for you!

Already a member?

Sign In Now »